Robert Spiera, Sebastian Unizony, Kenneth J. Warrington, Jennifer Sloane Lazar, Angeliki Glannelou, Michael C Nivens, Bolanie Akinlade, Wanling Wong, Yong Lin, Frank Buttgereit, Valerie Devauchelle-Pensec, Andrea Rubbert-Roth, Bhaskar Dasgupta
Abstract or description:The poster reports post-hoc results from the SAPHYR study on the resolution of PMR signs and symptoms regardless of glucocorticoid (GC) use and GC-free resolution of PMR signs and symptoms over time. GC-free resolution of PMR signs and symptoms was maintained from week 16 to week 52 in majority of patients treated with sarilumab 200mg Q2W + 14week GC.
Robert Spiera, Sebastian Unizony, Kenneth J. Warrington, Jennifer Sloane Lazar, Angeliki Glannelou, Michael C Nivens, Bolanie Akinlade, Wanling Wong, Yong Lin, Frank Buttgereit, Valerie Devauchelle-Pensec, Andrea Rubbert-Roth, Bhaskar Dasgupta
Abstract or description:The poster reports post-hoc results from the SAPHYR study on the resolution of PMR signs and symptoms regardless of glucocorticoid (GC) use and GC-free resolution of PMR signs and symptoms over time. GC-free resolution of PMR signs and symptoms was maintained from week 16 to week 52 in majority of patients treated with sarilumab 200mg Q2W + 14week GC.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
